Investor Relations

Charles River Associates (CRA) Announces Vice President Promotions


BOSTON--(BUSINESS WIRE)--Mar. 31, 2020-- Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced seven promotions to vice president. Patrick Augustine, in the Energy Practice, Brendan Kelly, Steven Kelly, and CĂ©cile Matthews, in the Life Sciences Practice, Matthew List, in the Antitrust & Competition Economics Practice, and Samuel Lynch and Rahul Surana, in the Finance Practice, have been promoted to the level of vice president.

“We are pleased to announce the promotions of these seven individuals to vice president,” said CRA’s President and Chief Executive Officer Paul Maleh. “Their commitment to serving their clients and colleagues with the highest quality of work reinforces the attributes we seek in leaders of the firm. We appreciate their many contributions and congratulate them on this career milestone.”

Patrick Augustine specializes in market analysis and strategy development within the electric utility and power market sectors. Mr. Augustine manages and performs power market assessments and other economic analysis in support of utilities, project developers, investors, and lenders in their energy asset development, financing, and integrated resource planning efforts. Mr. Augustine is a frequent writer and presenter in the power market space and has testified before multiple state utility commissions on various electric resource planning and power market analysis topics.

Brendan Kelly has extensive life sciences strategy consulting experience and expertise developing and leading projects that answer clients’ data-driven business questions. Dr. Kelly has worked on strategic and analytics-driven consulting projects across a number of areas including rare disease products, autoimmune diseases, central nervous system diseases, and biosimilar portfolios.

Steven Kelly has more than 20 years of experience working in health technology assessment, evidence-based medicine, health economics, and pricing and market access within the pharmaceutical industry. Prior to joining CRA, Mr. Kelly was Senior Director for Global Health & Value at Pfizer responsible for global market access of hospital products in Pfizer’s established products business. His expertise has focused on pricing and market access in Europe, with in-depth experience of health technology assessment in the UK. He has worked on a broad range of therapeutic areas throughout the lifecycle from Phase 2 to post loss of exclusivity.

Matthew List has extensive expertise in economic analyses related to mergers and acquisitions, non-merger investigations, and major litigation in a host of industries, including health care, sports and entertainment, wood products, retailing, and transportation. Mr. List has significant experience conducting quantitative and econometric analyses involving large datasets. He has managed client engagements involving complex antitrust litigation and has supported testifying experts in all facets of litigation from reports to depositions to trial. Mr. List has appeared on behalf of his clients before the Antitrust Division of the US Department of Justice.

Samuel Lynch specializes in the analysis of trading, structuring, markets, and valuation of financial securities, and has expertise in business valuation and the valuation of commercial contracts. Mr. Lynch supports clients in litigations and internal investigations involving potential allegations of market manipulation and spoofing. He has also managed numerous cases for clients in connection with securities litigations, complex commercial litigations, bankruptcies, and tax disputes. Prior to joining CRA, Mr. Lynch worked in investment banking in the municipal finance department at Goldman, Sachs & Co. and consulted at Monitor Group.

Cécile Matthews has more than 20 years of experience in strategy consulting for the life sciences industry. Ms. Matthews’ areas of expertise include pricing, reimbursement, and market access globally, with particular expertise regarding France. Throughout her career as a consultant, Ms. Matthews has provided her clients with strategic insights into how pricing and market access issues affect pharmaceuticals, medical devices, vaccines, and mobile health applications and how they are best addressed to optimize revenues.

Rahul Surana is an expert in disputes related to securities transactions and capital markets and has testified in US and International courts. He has more than 15 years of experience in class certification matters and has consulted on economic analyses, damage exposures, expected settlements, and loss causation arguments. Dr. Surana’s work has been used in both initial settlement discussions and for fairness of final class action settlements. He is a FINRA arbitrator and sits on a panel of judges to hear disputes between investors and securities firms. Dr. Surana has published in peer-reviewed journals and has presented in leading academic conferences.

About Charles River Associates (CRA)
Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at Follow us on LinkedIn, Twitter, and Facebook.

Media Relations
Charles River Associates

Jamie Bernard, IRC
Senior Associate
Sharon Merrill Associates, Inc.

Source: Charles River Associates